Plasma-Derived Therapeutics Market to Reach US$35.10B by 2033 | North America Leads Plasma-Derived Therapeutics Industry Growth

Plasma-Derived Therapeutics Market Size and Forecast

The global plasma-derived therapeutics market was valued at US$ 20.16 Billion in 2023. The market size reached US$ 21.26 Billion in 2024 and is expected to reach US$ 35.10 Billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Plasma-Derived Therapeutics Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/plasma-derived-therapeutics-market?rk

Recent Developments:
✅ October 2025: CSL Behring announced expanded manufacturing capacity for immunoglobulin (Ig) therapies in North America to address rising global demand for primary immunodeficiency (PID) and chronic inflammatory demyelinating polyneuropathy (CIDP). The expansion strengthens plasma fractionation capabilities and improves supply chain resilience.

✅ September 2025: Grifols introduced an enhanced hyperimmune globulin therapy targeting emerging infectious diseases. The innovation leverages advanced plasma screening technologies and improved purification processes to enhance safety and therapeutic efficacy.

✅ July 2025: Takeda Pharmaceutical Company expanded its plasma collection network across Asia-Pacific to support increasing demand for albumin and immunoglobulin products. The initiative aims to ensure stable plasma supply and strengthen regional self-sufficiency.

✅ May 2025: Octapharma launched a next-generation recombinant and plasma-derived hybrid coagulation factor therapy for hemophilia patients. The product focuses on extended half-life and reduced infusion frequency, improving patient adherence and treatment outcomes.

Mergers & Acquisitions:
✅ November 2025: Kedrion Biopharma completed the acquisition of a specialty plasma fractionation facility to expand its portfolio of rare disease therapies and increase production of immunoglobulin and coagulation factor products.

✅ September 2025: Bio Products Laboratory (BPL) was acquired by a global life sciences investment group to strengthen its plasma-derived portfolio and expand into emerging markets with high unmet medical needs.

✅ July 2025: ADMA Biologics acquired additional U.S.-based plasma collection centers to enhance vertical integration and ensure long-term raw material security for its immune globulin therapies.

✅ May 2025: LFB Group entered into a strategic acquisition agreement with a biotechnology firm specializing in rare plasma protein therapies, reinforcing its global footprint in immunology and critical care segments.

Key Players:
Takeda Pharmaceutical Company Limited, Johnson and Johnson (DePuy Synthes), Octapharma AG, Arthrex, Inc., Grifols, S.A., ADMA Biologics, Inc., CSL, Evolve Biologics Inc., Kamada Pharmaceuticals, and Bio Products Laboratory Ltd, among others.

Growth Forecast Projected:

The Global Plasma-Derived Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Plasma-Derived Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=plasma-derived-therapeutics-market?rk

Key Segments:

By Product Type
The market is segmented into Protein 55%, Coagulation Factors 35%, and Others 10%, with protein-based therapeutics dominating due to high demand for immunoglobulins and albumin in treating immune deficiencies and critical care conditions. Immunoglobulins account for a significant portion of plasma protein usage owing to rising cases of autoimmune and neurological disorders. Coagulation factors hold a substantial share driven by their essential role in hemophilia management. The "others" segment includes specialty plasma derivatives used in rare disease treatment.

By Application
By application, the market includes Primary Immunodeficiencies 35%, Hemophilia 30%, Idiopathic Thrombocytopenic Purpura (ITP) 15%, and Others 20%, with primary immunodeficiencies leading due to increasing diagnosis rates and long-term immunoglobulin therapy requirements. Hemophilia remains a key application segment supported by continuous replacement therapy using plasma-derived clotting factors. ITP treatment contributes steadily with growing awareness and improved access to plasma-based therapies. Other applications include neurological disorders, liver disease, and trauma management.

By End-User
The market is segmented into Hospitals & Specialty Clinics 60%, Homecare Services 25%, Ambulatory Surgical Centers 10%, and Others 5%, with hospitals and specialty clinics dominating due to the need for controlled administration and monitoring of plasma-derived products. Homecare services are growing rapidly as subcutaneous immunoglobulin therapies enable convenient at-home treatment. Ambulatory surgical centers contribute moderately through outpatient procedures and specialty treatments.

Regional Analysis
North America - 38% Share
North America leads with 38% share due to strong plasma collection infrastructure, high healthcare expenditure, and well-established reimbursement systems. The U.S. dominates the region with a large number of plasma donation centers and advanced biopharmaceutical manufacturing facilities.

Europe - 27% Share
Europe accounts for 27% share, supported by growing awareness of rare diseases and strong regulatory frameworks. Germany, France, Italy, and the UK are major contributors, with increasing demand for immunoglobulin therapies.

Asia Pacific - 20% Share
Asia-Pacific holds 20% share driven by rising healthcare access, increasing rare disease diagnosis, and expanding plasma fractionation facilities in China, Japan, and India. Government initiatives to strengthen domestic plasma supply support growth.

Latin America - 8% Share
Latin America captures 8% share, supported by improving healthcare infrastructure and rising hemophilia treatment programs in Brazil and Mexico.

Middle East & Africa - 7% Share
The Middle East & Africa region holds 7% share, driven by expanding specialty healthcare services and increasing awareness of immune-related disorders in GCC countries and South Africa.

Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/plasma-derived-therapeutics-market?rk

FAQ

Q1: What is the current size of the Plasma-Derived Therapeutics Market?

A: The Plasma-Derived Therapeutics Market was valued at US$ 20.16 Billion in 2023. The market size reached US$ 21.26 Billion in 2024 and is expected to reach US$ 35.10 Billion by 2033

Q2: How rapidly will the Market expand?

A: The Plasma-Derived Therapeutics market is projected to grow at a CAGR of 6.4% between 2025 and 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?rk

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?rk

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.